Ornithine Transcarbamylase Deficiency Market: Key Trends, Growth Drivers, Share & Forecast 2025–2034

The Business Research Company's Ornithine Transcarbamylase Deficiency Market: Key Trends, Growth Drivers, Share & Forecast 2025–2034

LONDON, GREATER LONDON, UNITED KINGDOM, May 15, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

The ornithine transcarbamylase deficiency OTC deficiency market has been showing strong growth in recent years. With a surge from $0.83 billion in 2024 to an expected $0.89 billion in 2025, the market is advancing at a compound annual growth rate CAGR of 7.1%. This historic upswing can be attributed to increased awareness of rare metabolic disorders, improvement in genetic screening and diagnostics, improved neonatal screening programs, and the rising prevalence of genetic testing in rare diseases.

Is the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Set to Witness Substantial Growth?

Over the next few years, the OTC deficiency market is expected to continue on its growth trajectory. The market is anticipated to reach $1.16 billion in 2029 at a CAGR of 6.8%. Factors contributing to this forecasted growth include increasing awareness and diagnosis, rising prevalence of urea cycle disorders, and a demographic shift toward rare disease treatment. Additionally, a rise in research and clinical trials, improved patient access to treatments, and advancements in genetic therapies and gene editing technologies are expected to fuel its growth.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Drives The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Growth?

One of the primary drivers propelling the growth of the ornithine transcarbamylase deficiency market is the increasing demand for gene therapies. Gene therapy involves the alteration of a person's genetic material to treat or prevent diseases. Its demand is spurred by the rising prevalence of genetic disorders which otherwise tend to have limited treatment options. Gene therapy offers a promising approach to addressing the root cause, rather than just managing symptoms.

By correcting the genetic mutation that disrupts the urea cycle, OTC deficiency is a perfect candidate for the potential of gene therapies. These therapies enable targeted treatment to restore metabolic function and prevent toxic ammonia accumulation. As of January 2024, according to the American Society of Gene & Cell Therapy, there was a 10% rise in the number of gene therapies entering Phase III in Q4 2023 - the first increase since Q3 2022. This rise in gene therapies is expected to drive the growth of the ornithine transcarbamylase deficiency market.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Who Are The Key Players In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Key industry players keeping the OTC deficiency market buzzing are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

What Are The Emerging Trends In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

One of the emerging trends is the focus on developing innovative therapies utilizing mRNA therapeutics. mRNA therapeutics instruct cells to produce specific proteins for therapeutic purposes. This type of therapy taps into the body's natural protein synthesis machinery to treat diseases, including genetic disorders, infectious diseases, and cancers. For instance, Arcturus Therapeutics Holdings Inc., a US-based biotech company, received Fast Track Designation in June 2023 from the U.S. Food and Drug Administration FDA for ARCT-810, its mRNA therapeutic candidate for OTC deficiency.

How Is The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segmented?

The OTC deficiency market is segmented into various categories. By product type, it is divided into DTX-301, SEL-313, SHP-641, PRX-OTC. When it comes to treatment type, it includes gene therapy, liver transplant, dietary management, and other treatment types. The market is also segmented by diagnosis, into genetic testing and ammonia level testing. Finally, the end-user categories include hospitals, specialty clinics, research institutes, and other end users.

What Is The Regional Analysis Of Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

In terms of geographic spread, North America was the largest region in the OTC Deficiency market in 2024. However, Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the report span across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Gene Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Iron Deficiency Injectable Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X